Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder

Psychopharmacology

Volumn 188, Issue 3, 2006, Pages 273-280

  Bech, Per ^a   Kajdasz, Daniel K ^b   Porsdal, Vibeke ^c  

^a FREDERIKSBORG GENERAL HOSPITAL   (Denmark)

^b ELI LILLY AND COMPANY   (United States)

^c Eli Lilly A/S   (Denmark)

Author keywords

Cymbalta; Depression; Dose response; Duloxetine; HAM D 17; HAM D6

Indexed keywords

DULOXETINE; MIRTAZAPINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MANTEL HAENSZEL TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME; UNITED STATES;

EID: 33748671793     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0505-1     Document Type: Article

References (49)

1. Angst J et al (1989) Consensus conference on the methodology of clinical trials of antidepressants. Pharmacopsychiatry 22:3-7
2. Bagby RM et al (2004) The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry 161:2163-2177
3. Bech P (2001) Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol 4:337-345
4. Bech P (2002) The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure. Acta Psychiatr Scand 106:252-264
5. Bech P et al (1975) Quantitative rating of depressive states. Acta Psychiatr Scand 51:161-170
6. Bech P et al (1981) The Hamilton Depression Scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 63:290-299
7. Bech P et al (1984) Assessment of symptom change from improvement curves on the Hamilton Depression Scale in trials with antidepressants. Psychopharmacology (Berl) 84:276-281
8. Bech P et al (2000) Meta-analysis of randomized controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 176:421-428
9. Bech P et al (2002) Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl) 163:20-25
10. Bech P et al (2004) Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 7:283-290
11. Bobes J et al (2003) A comparative psychometric study of the Spanish versions with 6, 17, and 21 items of the Hamilton Depression Rating Scale. Med Clin (Barc) 120:693-700 (Article in Spanish)
12. Borsboom D (2005) Measuring the mind. Conceptual issues in contemporary psychometrics. Cambridge University Press, Cambridge
13. Bulpitt CJ (1988) Medical statistics: meta-analysis. Lancet 2:93-94
14. Burroughs VJ et al (2002a) Cultural and genetic diversity and America: the need for individualized pharmaceutical treatment. National Pharmaceutical Council and National Medical Association. Last accessed on 12/06/2005 available from: http://www.npcnow.org/resources/PDFs/CulturalFINAL.pdf
15. Burroughs VJ et al (2002b) Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc 94:1-26
16. Bymaster FP et al (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871-880
17. Detke MJ et al (2002a) Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 36:383-390
18. Detke MJ et al (2002b) Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308-315
19. Detke MJ et al (2004) Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 14:457-470
20. DUAG (Danish University Antidepressant Group) (1999) Clomipramine dose-effect study in patients with depression: clinical endpoints and pharmacokinetics. Clin Pharmacol Ther 66:152-165
21. Dunlop SR et al (1990) Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull 26:173-180
22. Engels EA et al (2000) Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Stat Med 19:1707-1728
23. Entsuah R et al (2002) A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects. J Psychiatr Res 36:437-448
24. Fabre LF et al (1995) Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 38:592-602
25. Faries D et al (2000) The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 34:3-10
26. Gex-Fabry M et al (2004) Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol 59:883-891
27. Gibbons RD et al (1993) Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res 27:259-273
28. Goldstein et al (2004) Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 24(4):389-399
29. Hamilton M (1967) Development of a rating sale for primary depressive illness. Br J Soc Clin Psychol 6:278-296
30. Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. Academic, New York, NY
31. Lecrubier Y et al (1996) Clinical efficacy of milnacipran: placebo-controlled trials. Int Clin Psychopharmacol 11(Suppl 4):29-33
32. Licht RW et al (2005) Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression: is the total score a valid measure of illness severity? Acta Psychiatr Scand 111:144-199
33. Maier W, Philipp M (1985) Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 18:114-115
34. Mendels J et al (1993) Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 29:169-174
35. Moncrieff J, Kirsch I (2005) Efficacy of antidepressants in adults. BMJ 331:155-157
36. Nemeroff et al (2002) Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36(4):106-132
37. Niklson IA, Reimitz PE (2001) Baseline characteristics of major depressive disorder patients in clinical trials in Europe and United States: is there a transatlantic difference? J Psychiatr Res 35:71-81
38. O'Sullivan RL et al (1997) Sensitivity of the six-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 95:379-384
39. Paykel ES (1990) The use of the Hamilton Depression Scale in general practice. Psychopharmacol Ser 9:40-47
40. Peto R (1987) Why do we need systematic overviews of randomized trials? Stat Med 6:233-244
41. Pogue J, Yusuf S (1998) Overcoming the limitations of current meta-analysis of randomized controlled trials. Lancet 351:47-52
42. Preskorn SH (1998) Recent dose-effect studies regarding antidepressants. In: Balant LP, Benitez J, Dahl SG, Gram LF, Pinder RM, Potter WZ (eds) European cooperation in the field of scientific and technical research. European Commission, Brussels, Belgium, pp 45-61
43. Reisby N et al (1979) Clomipramine: plasma levels and clinical effects. Commun Psychopharmacol 3:341-351
44. Rifkin A (1997) SSRI optimal dose remains at issue. J Clin Psychiatry 58:87-88
45. Rudolph RL et al (1998) A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59:116-122
46. Ruhe H et al (2005) Clinical use of the Hamilton Depression Scale: is increased efficiency possible? A post hoc comparison of the Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression and Symptom Checklist-90 scores. Compr Psychiatry 46:417-427
47. Schmid JE et al (1991) An overview of statistical issues and methods of meta-analysis. J Biopharm Stat 1:103-120
48. Wernicke JF et al (1988) Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 24:183-188
49. Wernicke JF et al (1987) Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 23:164-168